Healthcare of Ontario Pension Plan Trust Fund Buys 522,678 Shares of Lantheus Holdings, Inc. $LNTH

Healthcare of Ontario Pension Plan Trust Fund grew its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 686.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 598,857 shares of the medical equipment provider’s stock after acquiring an additional 522,678 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Lantheus were worth $45,423,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Abel Hall LLC lifted its stake in shares of Lantheus by 4.6% during the 1st quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock worth $297,000 after purchasing an additional 172 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares in the last quarter. Blue Trust Inc. boosted its position in Lantheus by 30.3% during the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 230 shares in the last quarter. Vident Advisory LLC grew its stake in Lantheus by 0.5% in the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock valued at $2,979,000 after purchasing an additional 230 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its stake in Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

LNTH has been the subject of several analyst reports. Mizuho increased their price target on shares of Lantheus from $115.00 to $120.00 and gave the company a “market outperform” rating in a research report on Wednesday, July 15th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $115.00 price objective on shares of Lantheus in a research report on Monday, June 29th. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a research note on Thursday, May 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Finally, Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.43.

Lantheus Trading Up 1.1%

Shares of NASDAQ:LNTH opened at $104.82 on Friday. The business’s 50-day moving average is $103.36 and its 200 day moving average is $85.56. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $111.86. The firm has a market capitalization of $6.82 billion, a P/E ratio of 25.26 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the company earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts predict that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.